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Women have a high incidence of chronic venous disease. Venous occlusive disease can lead to signiﬁcant morbidity and
even death. Factors such as genetics, medications, and diseases can play a role in the development of venous thrombosis.
In women, pregnancy can lead to a hypercoagulable state and a greater risk of venous complication. Awareness and
education will be very important in the future to help identify those patients at risk. (J Vasc Surg 2013;57:46S-8S.)It is estimated that >33.3% of women will have chronic
venous disease compared with <20% of men. When look-
ing at varicose veins alone, the prevalence is thought to
be even higher, reaching almost 75% of women. Typically,
venous insufﬁciency is equated with superﬁcial venous
valvular incompetence. Venous thrombosis and thrombo-
embolism (VTE) can potentially cause signiﬁcant mor-
bidity from venous occlusions and stenoses and death
from pulmonary embolisms. Virchow’s triad, named after
the German physician Rudolph Virchow, identiﬁes the
factors thought to be paramount in the development of
thrombosis.1 These factors include:
1. Injury to the endothelial lining resulting in coagula-
tion; for example, injury could occur from anatomic
problems such as compression, as seen in May-
Thurner Syndrome and Paget Schroetter syndrome.
Injury can occur in traumatic situations or secondary
to iatrogenic injury.
2. Stasis or ﬂow disturbances leading to stagnation and
inefﬁcient blood ﬂow in a given circulatory bed, as
seen in venous valvular disease.
3. Thrombophilia caused by an underlying acquired or
congenital hypercoagulable condition. The more
severe congenital coagulation disorders include anti-
thrombin III deﬁciency, protein C deﬁciency, and
protein S deﬁciency.2 Fortunately, these conditions
occur rarely. Antithrombin III deﬁciency and protein
C deﬁciency occur in 0.2% of the population.3 Milder
conditions include factor V Leiden gene mutation
and prothrombin G20210S mutation, occurring
much more commonly in the general population.3,4
Acquired hypercoagulable states include antiphospho-
lipid syndrome, anticardiolipin antibodies, lupus anti-
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://dx.doi.org/10.1016/j.jvs.2012.10.120The risk of VTE is 1 to 2 per 1000, which increases
with age.6 The incidence in women during childbearing
years is higher than in men, but then later in life, drops
to below the incidence of VTE in men.7 The risk of recur-
rence is actually higher in patients with a history of VTE,
a history of cancer, lupus anticoagulant, or a hereditary
thrombophilia.8 Kyrle et al9 concluded that the risk of
recurrent VTE was almost four-times higher in men than
women. Other risk factors for thrombophilia include preg-
nancy, oral contraceptive (OC) use and hormonal replace-
ment therapy, and obesity.10,11
Given the signiﬁcant morbidity and sometimes death
associated with thrombophilia, questions have been raised
about the need for widespread testing. Very concise guide-
lines have been put forth in the United Kingdom.10 They
found that testing is not indicated in unselected patients.
However, testing should be initiated in patients who
present at a young age, patients with two or more family
members with history of thrombophilia, children with
purpura fulminans, and patients receiving oral Vitamin K
antagonists who develop skin necrosis. Because pregnancy
carries a risk of thrombosis that is ﬁvefold to tenfold
increased compared with nonpregnant age-equivalent
women, testing was not recommended.
In contrast, pregnant women with a previous event
thought to be caused by a minor provoking factor, or
with a ﬁrst-degree relative with a history of an event
provoked by a minor factor or pregnancy, might beneﬁt
from testing. The guidelines recommended that patients
with maternal thromboembolism, who are high risk for
thrombosis, should be treated with anticoagulation, no
matter what the testing would show. Because testing by
itself does not determine recurrence risk, treatment should
ensue based on the patient’s clinical presentation.
The use of OC and the role this plays in VTE must be
addressed. By deﬁnition, this is an issue that is unique to
women. With the advent of OC, venous thromboses and
pulmonary embolisms were reported in women using
OC, and an association with myocardial infarction and
stroke soon followed. Over the years, attention has been
given to the effect that the estrogen and progestin content
has on the risk of VTE.12 First-generation and second-
generation OCs containing low-dose progestin alone are
associated with a lower risk of VTE than combination prep-
arations.13 Prothrombotic disorders then were recognized
as increasing the risk of VTE, especially in women taking
OC. There is a fourfold increase risk of VTE in patients
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women not on OC. Those women who carry the mutation
and are on OC have an astounding 35-fold risk of VTE.14
The other genetically acquired thrombophilic states are
also associated with a risk of VTE in patients on OC.15
Women with thrombophilia have a 10-times higher risk
of developing OC-associated VTE within the ﬁrst year of
use rather than later.16 History of VTE, thrombophilia,
smoking, advanced age, and known risk factors for cardio-
vascular disease have been used to try to identify those
patients using OC at risk for VTE.17
Physiologically, pregnancy creates a hypercoagulable
condition.18 Risk factors associated with VTE in pregnant
patients include advanced maternal age (>35 years),
obesity, and cesarean section.19 Treatment requires antico-
agulation using low-molecular-weight heparin because it
does not cross the placenta, given in once-daily or twice-
daily weight-based dose.20 In addition, because a history
of VTE increases the risk of recurrence during pregnancy,
compression stockings are recommended during pregnancy
and postpartum. Postpartum anticoagulation for 6 weeks is
recommended in women with previous VTE. Those
patients with high-risk thrombophilias or history of greater
than two previous episodes of VTE should be considered
for prophylactic anticoagulation antepartum.21
Recent studies have demonstrated the contribution of
ileofemoral obstruction proximal to the conﬂuence of the
profunda and femoral veins is far greater than previously
thought. Venous obstruction is classiﬁed into primary
and secondary. Primary venous occlusive disease has
been referred to by many different names, including
May-Thurner syndrome, Cockett syndrome, and iliac
vein compression syndrome. However, it is most accu-
rately referred to as a nonthrombotic iliac vein lesion
(NIVL). Secondary lesions are chronic post-thrombotic
lesions.
Presentation of veno-occlusive disease, despite the
underlying etiology, is similar. These lesions can present
with symptoms of chronic venous insufﬁciency ranging
from leg pain to pigment changes to venous stasis ulcera-
tions. Leg swelling is commonly seen with obstructive
lesions of the iliac veins. Pain out of proportion for physical
examination ﬁndings associated with some degree of leg
swelling is a common presentation.
On venography, obstructive lesions of the iliac vein are
felt to be hemodynamically signiﬁcant if associated with
collateral formation. But some have found hemodynami-
cally signiﬁcant stenoses in the absence of collateral forma-
tion. Thus, additional imaging modalities are required to
diagnose obstructive lesions. Intravascular ultrasound
(IVUS) has been shown to be a superior imaging modality
and can better deﬁne intraluminal stenoses, webs, or
trabeculations.
NIVLs have a distinct appearance on IVUS imaging.
These lesions are typically <2 cm in length and involve
a single venous segment. The overlying artery can be seen
compressing the vein in the area of stenosis. The venous
wall appears normal on IVUS imaging. Post-thromboticobstructions are more diffuse, involving an entire venous
segment, and may involve multiple segments as thrombus
propagates to the conﬂuence of the proximal venous
tributaries. The vein wall is irregular and ﬁbrotic in the
areas of stenosis. Chronic thrombus may also be seen
within the area outﬂow obstruction.
Although multiple studies are available to look at the
treatment of veno-occlusive disease, Neglen et al22 re-
ported the outcome of 982 venous lesions treated during
an 8-year period. This single series illustrates the increased
prevalence of this disease process in women and how the
underlying etiology affects outcomes. In this series, the
ratio of women to men was 2.6:1, with a left-to-right
predominance of 2.4:1. Primary lesions accounted for
518 of the treated lesions, with the remainder being
secondary or post-thrombotic. All lesions were diagnosed
by venography and IVUS. All lesions were successfully
treated with stenting, with a low morbidity and mortality.
Most patients described major symptom relief after the
intervention. Patency rates at 72 months for primary
lesions were 79% primary patency, 100% primary assisted
patency, and 100% secondary patency. Secondary lesions
had a 57% primary patency, 80% primary assisted patency,
and 86% secondary patency.
A second series of 163 limbs in 150 postmenopausal
women describes a unique and largely undiagnosed group
of women.23 These women represented 9% of all limbs
treated for chronic venous disease and 18% of those stented
for lower extremity edema alone. The treated women were
a mean age of 67 years (range, 55-72 years). The left-to-
right ratio was 2:1, but approximately 20% had signiﬁcant
stenoses in the bilateral iliac veins. Other ﬁndings were
NIVLs in 65% and secondary lesions in 35%. After treat-
ment, all women reported signiﬁcant improvement in
pain, swelling, and quality of life scores.
This illustrates the permissive nature of these lesions.
Although they are present in many women, they do not
become truly symptomatic until a second component of
the venous system fails or another physiologic alteration
occurs, such as menopause, that allows for the manifesta-
tion of symptoms related to venous outﬂow obstruction.
Postmenopausal women who develop lower extremity
edema are often subjected to a battery of tests that rarely
yield a diagnosis or treatable cause. The swelling is
commonly attributed to an unknown, multifactorial cause
or felt to be an adverse effect of medications. Many times
these women are prescribed diuretics, with minimal effect
on their symptoms. Women with lower extremity edema
and pain merit venography and IVUS imaging to evaluate
for veno-occlusive disease.
Venous thrombosis, embolism, and ultimately, venous
occlusive disease are conditions that can lead to signiﬁcant
morbidity and death. Conditions that render patients more
at risk include trauma, chronic venous insufﬁciency and
stasis, and thrombophilia. As we gain more understanding
of the underlying etiology, diagnosis and treatment can
then be undertaken to minimize the long-term sequelae
of VTE and occlusive disease.
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